Metabolic dysfunction-associated steatohepatitis
Drug research and approvals for metabolic dysfunction-associated steatohepatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 97 studies of metabolic dysfunction-associated steatohepatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 97
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 97 recruiting on ClinicalTrials.gov ↗- SMART Diets for MASLDNCT07459504 · Phase 2 · Michigan State University · starts Nov 5, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Resmetirom in Patients With MASH and HFpEFNCT07830758 · Phase 1 · Madrigal Pharmaceuticals, Inc. · starts Oct 16, 2026
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisNCT07848191 · Phase 4 · Madrigal Pharmaceuticals, Inc. · starts Oct 7, 2026
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDNCT07877272 · Not reported · University Hospital Muenster · starts Oct 5, 2026
- A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal ImpairmentNCT07807059 · Phase 1 · Fujian Shengdi Pharmaceutical Co., Ltd. · starts Sep 9, 2026
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Phase 4 · West China Hospital · starts Sep 1, 2026
- A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated…NCT07660848 · Phase 2 · Fujian Shengdi Pharmaceutical Co., Ltd. · starts Aug 14, 2026
- Study of Resmetirom in Children and Adolescents With MASHNCT07763015 · Phase 2 · Madrigal Pharmaceuticals, Inc. · starts Aug 1, 2026
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164 · Phase 3 · Altimmune, Inc. · starts Jul 30, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 22, 2026 | A phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult…EFIMOSFERMIN ALFA (GSK6519754) | GSK | Pending |
| Jul 21, 2026 | A phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult…EFIMOSFERMIN ALFA (GSK6519754) | GSK | Ongoing |
| Jul 14, 2026 | A phase 2b, randomized, double-blind, placebo-controlled study of aln-cideb in adults with fibrotic metabolic dysfunction associated steatohepatitis (mash)ALN-1699976 (ALN-CIDEB) | Regeneron | Pending |
| Apr 30, 2026 | A phase 3, randomized, double-blind, placebo-controlled, 3-arm study to investigate the safety and tolerability of efimosfermin alfa in participants with known…EFIMOSFERMIN ALFA (GSK6519754) | GSK | Ongoing |
| Apr 29, 2026 | A phase 3, randomized, double-blind, placebo-controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with…GSK6519754 (EFIMOSFERMIN ALFA) | GSK | Ongoing |
| Dec 12, 2025 | A phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of bi 3802876 in participants…BI 3802876 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pending |
| Jul 23, 2024 | A phase 3 study to evaluate the efficacy and safety of pegozafermin in subjects with compensated cirrhosis due to metabolic dysfunction-associated…PEGOZAFERMIN (BIO89-100) | Roche | Ongoing |
| Jun 6, 2024 | A phase 2a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efinopegdutide (mk-6024) in adults with compensated…MK-6024 | Merck & Co. (MSD) | Closed |
| May 3, 2024 | A phase 3 study to evaluate the efficacy and safety of pegozafermin in subjects with metabolic dysfunction associated steatohepatitis (mash) and fibrosisBIO89-100 | Roche | Ongoing |
Medicines Authorised in the EU
Newest first| Mar 26, 2026 | Kayshildsemaglutide | Novo Nordisk A/S | EMA ↗ |
| Aug 18, 2025 | Rezdiffraresmetirom | Madrigal Pharmaceuticals EU Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA